am 10.40 deloughery
DESCRIPTION
TRANSCRIPT
The Woman at Risk for Blood Clots: Guidelines for Screening & Management
Tom DeLoughery, MD FACP FAWM
Oregon Health and Sciences University
DISCLOSURE
Relevant Financial Relationship(s)
Speaker Bureau - None
Consultant – Amgen
Grants - Alexion
Estrogen and Thrombosis• Key principles
– Estrogen in any dose causes thrombosis
– Drugs that act like or oppose estrogen causes thrombosis
– Hypercoagulable states synergize with estrogen effect
– Age is a hypercoagulable state
– The past predicts the future
Women’s Deaths from VTE vs Age
Age Death/Million
15-24 0.3
24-34 3.4
35-44 9.9
Estrogen Containing Contraception
• Most common medication in young woman– 12 million users
• First associated with DVT in 1961
• Despite reduction in estrogen, risk remains
Overall Risk
• Overall risk of thrombosis is increase 3 fold with use of oral contraception– 1-3:10,000 to 3-6:10,000
• Risk higher with 1st and 3rd generation pills– 1st – huge estrogen doses– 3rd- progestin component
Overall Risk
Lewis MA Human Reproduction 1999
Overall Risk 2nd vs 3rd
Kemmeren, et al BMJ 2001
3rd Generation Pills
• Desogestrel, gestodene, and norgestimate
• Reduced androgenic side effects
• RR over 2nd generation pills 1.7-2.6– 1-2 extra DVT/10,000 users
Drospirenone
• Progestin with antimineralocorticoid and antiandrogen effect
• Risk varies in studies but appears double of 2nd generation pills– FDA ~ 1.5
Progestin Only
• Pills (northethisterone, desogestrel)– No increased risk
• Injectable – 2.2-3.6 increase risk
– Patient selection?
Levonorgestrel IUD
• No increase risk of thrombosis
• Decrease menstruation can be an advantage in women on anticoagulation
Modifiers of Risk• Timing: increased in first three
months of use– RR as high as 12 reported
• Risk does persist throughout time of use
• With stopping OCP, risk disappears after three months
Age of Patient
• Risk higher in older patients– Additive effect with thrombophilia of
aging
Risk of DVT vs Age
BMJ 2011:343:d6423
Hypercoagulable States
• Dramatic interactions with hypercoagulable states
• RR range from 10-99!
• Highest in OCP that contain desogestrel or gestodene (3rd generation)
• ABSOLUTE risk is still 28-50/10,000
FVL and OCP
FVL OCP RR CI
- - 1
- + 3.7 2-6
+ - 6.9 2-28
+ + 34.7 7-224
Lancet. 1995 Dec 16;346(8990):1593-6
Should Woman be Screened for Hypercoagulable States?
• No utility in screening!
• Will deny contraception to > 60 women to prevent one DVT
OCP Recommendations:Hypercoagulable State
• No general screening• + Hypercoagulable state but NO
thrombosis– Controversial– If strong need for OCP - ok– If strong family history - no
OCP Recommendations: History of Thrombosis
• If not anticoagulated - no estrogen containing OCP– Progesterone ok– LNG IUS ok
• If anticoagulated estrogen containing OCP ok– Unclear if any increase thrombotic risk– Unplanned pregnancy while anticoagulated
difficult
Rings and Patches
• Patches have same to higher risk as pills
• Rings unknown but probably similar to patches/pills
• Same precautions apply as OCP
HRT
• Overall risk with combined therapy is RR of 2
• However baseline risk is 1:1000– Absolute risk is 1:500
• Estrogen only replacement RR is 1.33
Hypercoagulable States
• Marked synergy with HRT and hypercoagulable states
• RR 6.7-17
• Absolute risk is higher due to age effect
FVL and HRT
FVL HRT RR CI
- - 1
- + 3.2 2-6
+ - 3.9 1.3-11.2
+ + 15.5 3-76
Br J Haematol. 2002 Mar;116(4):851-4
• 71 vs 60 women with history of DVT randomized to HRT
• HRT: 10% DVT (3 PE, 1 CVT)– 8.5%/year
• Placebo: 2.2%– 1%/year
• Trial terminated early
RCT: HRT and Prior Thrombosis
HRT Patch
• Unlike contraceptive patch, the risk of thrombosis appears to be lower with HRT patch
• Several studies show no activation of coagulation
• Needs to be prospective studied
Recommendations: HRT
• History of DVT: no HRT unless anticoagulated
• + Hypercoagulable state: No– Patch - ???
• On anticoagulation: Yes
Estrogen Related Thrombosis and Risk of Future Thrombosis
• “Estrogen” is most common risk factor for provoked DVT in woman
• Increasing data on risk of future DVT
JAMA. 2005 May 18;293(19):2352-61
Estrogen Related Thrombosis and Risk of Future Thrombosis
• Data from Prevent trial– With non-hormone-related thrombosis
• Recurrence rate 15.0%
– With hormone-related thrombosis • Recurrence rate 5.0%
– With hormone-related thrombosis • 58% lower risk than men (HR 0.42)
– With hormone-related thrombosis • 46% lower recurrence risk than other women (HR 0.54)
Estrogen Related Thrombosis and Risk of Future Thrombosis
• Women who have a DVT due to “estrogen” have very low rates of recurrence
• Not influenced by most genetic hypercoagulable states
Estrogen like Drugs
• All drugs that interfere with estrogen appear to be prothrombotic
• Tamoxifen raised DVT rates 3 fold
• Raloxifene doubles risk
• Aromatase inhibitors also slightly increase risk
Assisted Reproduction• Increasing reports of DVT with ART
– Mainly upper extremity– Appears to be associated with
hyperstimulation syndrome
• Should treat for at least 6 weeks– Longer if pregnancy successful
• Unclear prophylaxis is useful in at risk women
Pregnancy
• Multiple factors lead to hypercoagulable state– Estrogens
– Venous stasis due to anatomical changes
– Bed rest
Pregnancy
• Multiple issues– Risk of DVT
– Use of anticoagulants
– Hypercoagulable states and adverse pregnancy outcomes
Modifiers of Risk: Age
• Overall risk is 1:1000– 50% post-partum
• Risk rises with age
• Major concern as women are having children at older age
Rates of VTE by Age(DVT/1000 Pregnancies)
1.471.58 1.67 1.73
2.13
2.75
0
0.5
1
1.5
2
2.5
3
<20 20-24 25-29 30-34 35-39 >40
Age and Death from VTE
Age Death/Million
No-OCP OCP Pregnancy
15-24 0.3 6.0 5.0
24-34 3.4 7.9 7.7
35-44 9.9 13.4 19.2
Risk Modifiers: History of DVT
• Women with history if DVT at higher risk of recurrence– Risk is 2-8%
• Higher if idiopathic DVT
Risk Modifiers: Bed rest
• > 3 days of bed rest increase rate from 0.8/1000 to 15.6/1000
• Venous stasis vs hypercoagulable state
• Prophylaxis?
Hypercoagulable States
• Again a profound influence
• RR 57 in meta-analysis
• Most women with DVT during pregnancy have hypercoagulable state
Therapy
• Warfarin: No!
• New drugs: No!
• Heparin
• Low molecular weight heparin
• (Fondaparinux)
Warfarin
• Teratogenic – Bone development
– Increased incidence of CNS defects?
– Highest risk 9-12 weeks
– Greatest with dose > 5 mg/day
Standard Heparin in Pregnancy
• aPTT unreliable in pregnancy
• Must use “heparin levels” (anti-Xa) even with prophylaxis– PK of UFH changed in pregnancy
• Leads to osteoporosis in 36% of women– Not dose dependent!
• Inconvenient dosing
Low Molecular Weight Heparin
• Safe and effective in pregnancy– Abundant use
• Does not cross placenta
• Predicable dosing
• Lesser risk of osteoporosis
LMWH in Pregnancy• Prophylaxis
– Enoxaparin 40mg/day– Dalteparin 7500q day or 5000 q12\– No need to check levels
• Therapy– Usual dose
• Enoxaparin 1mg/kg q12hours
– Check levels qmonth• 4 hours after dose• 0.7-1.1 anti-Xa units
Duration of Therapy
• 3 months or 6 weeks after delivery for first thrombosis
• 2 DVTs: life long• “Strong” hypercoagulable state: lifelong
– True APLA, MPS, PNH, cancer• “Weak” hypercoagulable state: does not effect
duration• Note: warfarin is NOT a contraindication to
breast feeding
History of DVT
• Women with history of DVT needs prophylaxis • LMWH--->warfarin/LMWH for 6 weeks
– Provoked DVT just post-partum
• Hypercoagulable state but no DVT history– Controversial!– 1-10% rate with factor V Leiden– Post-partum prophylaxis
Hypercoagulable States
• Controversial if all women with thrombosis during pregnancy need evaluation– Establish duration of therapy– Establish type of therapy– Family studies and interventions
• Etiologies may be found in up to 60% of women
What to Evaluate• Antithrombin III• Protein C• Protein S• Factor V Leiden• Prothrombin gene mutation• Antiphospholipid antibodies
– Lupus inhibitor– Anticardiolipin antibodies
• MTHFR – NO!
When to Evaluate• During pregnancy
– Antiphospholipid assays– Antithrombin levels– Factor V Leiden– Prothrombin gene defect
• 3 month post-partum– Protein C– Protein S
• Note: Protein S can drop to very low levels during pregnancy
Patient on Warfarin Planning Pregnancy
• Frequent pregnancy checks
• Change to LMWH when test is positive
• Alternative is to change to LMWH
Are Pregnancy Complications Thrombotic?
• Placental ischemia results in:– Decreased fetal growth
– Fetal death
– Pregnancy induced hypertension
Frequent Miscarriages
• Placenta becomes blood supply to fetus 8-9 weeks
• Early losses due to many factors
• Strong association with hypercoagulable states if miscarriage after 10 weeks.
Overall Risk
• Miscarriages 16:100
–2-3 trimester 1-2:100
• Preeclampsia 2-4:1000
• How dose hypercoagulable states influence this risk?
Risk of Pregnancy Loss with Thrombophilia
Disorder OR for Preg Loss
Factor V Leiden 2-5
Prothrombin Gene Mutation
2-9
Protein C Deficiency 2-3
Protein S Deficiency 2-40
Combined 5-14
Am J Obstet Gynecol. 2004 Aug;191(2):412-24.
Who Should Be Evaluated?
• No use in screening
• + Family history
• + Thrombosis
• Pregnancy complications (HELLP,PIH,....)
• 1 or more fetal death after 10 weeks
• 1 or more premature birth due to PIH or FUGR
• 3 or more miscarriages before week 10
LMWH Prophylaxis
• Antiphospholipid syndrome – Yes
• Unselected women with 2 or more losses – 2 RCT say No
• Definite Thrombophilia - ?
• Multiple last losses - ?
Recommendations: Therapy• Consider prophylaxis with one or
more unexplained loss and hypercoagulable state
• Difficulty is in woman with no identifiable hypercoagulable state– Consider therapy if multiple early
losses, late losses, or evidence of placental thrombosis
Summary
• Risk of thrombosis with estrogen is dependent on – Age
– Thrombophilia
– History of thrombosis